Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy or might not even be anticipated. The Company has based these forward-looking statements on current estimates and assumptions which we believe are reasonable and which are made to the best of our knowledge. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic or competitive conditions, changes in reimbursement, regulatory compliance issues, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, cyber security issues and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) Annual Report on Form 20-F under the heading “Forward-Looking Statements” and under the headings in that report referred to therein, and in FMC AG & Co. KGaA's other reports filed with the Securities and Exchange Commission (SEC) and the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse).

Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.

If not mentioned differently the term net income refers to the net income attributable to the shareholders of Fresenius Medical Care AG Co. KGaA. The term EMEA refers to the region Europe, Middle East and Africa. Amounts are in Euro if not mentioned otherwise.
DEMONSTRATING COMMITMENT TO PATIENT CARE

ENHANCING PATIENTS’ CHOICE

With the acquisition of NxStage, we have expanded our offering in home dialysis, giving our patients more independence and quality of life.

MAINTAINING SUPERIOR CARE

In 2019, we continued to improve clinical quality and achieved the best result in the U.S. government’s Five-Star dialysis clinics rating.

RAISING AWARENESS, PROVIDING SUPPORT

The Fresenius Medical Care Foundation is investing in innovative programs to help patients, families, and communities impacted by kidney disease.

LINKING RESEARCH AND PRACTICE

We aim to link research and therapy more closely and thus develop even better therapies. To this end, we have established the Global Medical Office.
Solid Q4 performance

Full year guidance achieved

Investments in home dialysis and growth markets as planned

Cost optimization initiatives as planned

23rd consecutive dividend increase proposed

Outlook 2020 confirmed
FULL YEAR 2019 | GROWTH CONTINUED

+2% Clinics
3,994

+4% Treatments
52,148,107

+4% Patients
345,096

Quality remains on a consistently high level
FULL YEAR 2019 | LEVERAGING OUR GLOBAL FOOTPRINT

NORTH AMERICA
2,579 clinics
211,064 patients

LATIN AMERICA
234 clinics
34,810 patients

EMEA
781 clinics
66,217 patients

ASIA-PACIFIC
400 clinics
33,005 patients

45 Production sites worldwide
Products in ~150 countries
Services in ~50 countries
~121,000 employees worldwide

© │ Press Conference │ FY 2019 │ 2/20/2019 │ Page 6
## FULL YEAR 2019 | DELIVERED ON GUIDANCE

<table>
<thead>
<tr>
<th></th>
<th>2019 € million</th>
<th>2018 € million</th>
<th>Growth</th>
<th>Guidance in cc</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td>17,477</td>
<td>16,547</td>
<td>6%</td>
<td>2%</td>
</tr>
<tr>
<td>Revenue adjusted</td>
<td>17,329</td>
<td>16,026</td>
<td>8%</td>
<td>5%</td>
</tr>
<tr>
<td><strong>Operating income</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operating income</td>
<td>2,270</td>
<td>3,038</td>
<td>-25%</td>
<td>-28%</td>
</tr>
<tr>
<td>Operating income adj.</td>
<td>2,296</td>
<td>2,292</td>
<td>0%</td>
<td>-4%</td>
</tr>
<tr>
<td><strong>Net income</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net income</td>
<td>1,200</td>
<td>1,982</td>
<td>-39%</td>
<td>-42%</td>
</tr>
<tr>
<td>Net income adj.</td>
<td>1,369</td>
<td>1,341</td>
<td>2%</td>
<td>-2%</td>
</tr>
</tbody>
</table>

cc = constant currency

- Adjusted revenue growth was at the mid-point of our guidance
- As announced, FY 2019 was characterized by investments in future growth
- In line with our guidance, adjusted net income was slightly below last year’s level
### FULL YEAR 2019 | ALL REGIONS CONTRIBUTE

<table>
<thead>
<tr>
<th>Region</th>
<th>Revenue (€ million)</th>
<th>Organic Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>NORTH AMERICA</td>
<td>12,195</td>
<td>0% cc</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4%</td>
</tr>
<tr>
<td>EMEA</td>
<td>2,693</td>
<td>4% cc</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4%</td>
</tr>
<tr>
<td>ASIA-PACIFIC</td>
<td>1,859</td>
<td>7% cc</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7%</td>
</tr>
<tr>
<td>LATIN AMERICA</td>
<td>709</td>
<td>21% cc</td>
</tr>
<tr>
<td></td>
<td></td>
<td>17%</td>
</tr>
</tbody>
</table>

1 Organic growth

- Strong overall organic growth of 5%
- North America growth rate (cc) reflects divestiture of U.S. Care Coordination activities in 2018

cc = at constant currency
SERVICES | STRONG UNDERLYING GROWTH TO CONTINUE

- Health Care Services accounted for 79% of revenue in 2019
- Solid volume and organic growth
- Positive impact of acquisitions
- Number of clinics, patients and treatments increased across all regions
PRODUCTS | STRONG UNDERLYING GROWTH TO CONTINUE

- Health Care Products accounted for 21% of revenue in 2019
- North America and Asia-Pacific with strong contribution to growth
- Higher sales of Home HD products following the acquisition of NxStage

1 Organic Growth
INVESTING INTO EXPANSION OF HOME TREATMENTS
- Home training facilities, educational staff and materials along with scaling the distribution infrastructure
- Reducing Capex for De novo clinics

INCREASING AWARENESS
- Early recognition of Chronic Kidney Disease
- Smooth transition to dialysis

TARGET 2022:
15%+
of treatments in the U.S. performed in a home setting
CAPTURING GROWTH IN DEVELOPING ECONOMIES

RECENT INVESTMENTS IN CHINA

- Expansion of production capacities to support growing services business
- Number of clinics almost doubled
- Acquisition of local hospitals and dialysis centers
- First dialysis machine (4008A) engineered specifically for developing economies rolled out in 2019

WHY NOW?

- China has the most dialysis patients in the world and is Fresenius Medical Care’s second-largest product market
- Only around 45% of kidney patients in China can be treated at present
- China is undergoing a process of profound change and is opening up in the health care sector
GLOBAL SUSTAINABILITY PROGRAM INITIATED

Acting responsibly to achieve business success as well as environmental and social progress

- **8 materiality areas** will be addressed
- Responsibility with the Sustainability Decision Board, **headed by the CEO**
- Involvement of senior representatives **in all regions and global functions**
SHARE PRICE DEVELOPMENT

FME, INDEXED, IN %

+32%
DIVIDEND INCREASE PROPOSED

DIVIDEND PER SHARE IN EUR

CAGR+10.7%

2015 2016 2017 2018 2019

0.80 0.96 1.06 1.17 1.20

DIVIDEND PROPOSAL 2019

- 23rd consecutive dividend increase proposed
- Dividend proposal with focus on dividend continuity despite lower net income

SHARE BUYBACK ON TRACK

- Volume up to €1bn
- Shares repurchased with a volume of €600m by the end of 2019

Dividend for 2019 of €1.20 to be approved by the AGM on May 19, 2020
> Leverage on our investments in **home dialysis** and **developing economies**

> Further **expansion** of our global services footprint

> U.S. President’s **Executive Order**

> Implementation of a **Global Sustainability Program**
2019: EUR 17,477m

2019: EUR 1,236m

Excluding special items: Special items are effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance.
Q&A

YOUR QUESTIONS ARE WELCOME.

Rice Powell – CEO
Helen Giza – CFO